Monthly Archives: March 2022

BILLERICA, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will participate at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place on March 28-30, 2022.

Read more from the original source:
SeqLL to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Guggenheim Genomic Medicines & Rare Disease Day on Friday, April 1, 2022, at 12:00 p.m. E.T.

More:
GBT Announces Participation at the Guggenheim Genomic Medicines & Rare Disease Day

- Confirmed partial response in one of the first three metastatic castration-resistant prostate cancer (mCRPC) patients treated with BPX-601 in Phase 1/2 study -

Read the original post:
Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update

WINNIPEG, Manitoba, March 24, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), today announced its fourth quarter and full year 2021 financial results.

Read more here:
Kane Biotech Announces Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- ?Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the full year ended December 31, 2021.

See the rest here:
Imago BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results

TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX - XLY) (OTCQX: CBWTF) ("Auxly" or the "Company"), a leading consumer packaged goods company in the cannabis products market, announced today that it will report earnings results for its fourth quarter and full year ended December 31, 2021, on Thursday March 31, 2022, before the financial markets open.

See the rest here:
Auxly to Report Fourth Quarter and Full Year 2021 Financial Results on March 31, 2022

-- Proposal of one-tier board structure & appointment of three new directors --Mechelen, Belgium; 24 March 2022, 21.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 2021 and announces extraordinary and annual shareholders’ meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET), respectively, at the registered office of the Company.

Original post:
Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders’ meetings

Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs

Follow this link:
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Continued Progress Towards Optimizing Clinical Development Plans

Go here to see the original:
Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update

Basel, 25 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new data for its approved and investigational medicines across neurological disorders will be presented at the 74th American Academy of Neurology (AAN) Annual Meeting being held 02-07 April in Seattle and virtually 24-26 April 2022. These data include twenty-four abstracts highlighting Roche’s expansive neuroscience portfolio across five therapeutic areas, including OCREVUS® (ocrelizumab) in relapsing, secondary and primary progressive multiple sclerosis (RMS, SPMS and PPMS), EVRYDSI™ (risdiplam) in spinal muscular atrophy (SMA), ENSPRYNG™ (satralizumab) in neuromyelitis optica spectrum disorder (NMOSD), along with data from investigational programs in Alzheimer’s disease (AD) and Duchenne muscular dystrophy (DMD).

See the rest here:
Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting